The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Optimization of Melanoma Treatment Advances Remains a Work in Progress
May 19th 2015Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.
Study Offers Solution for HER2 Resistance in Breast Cancer
May 19th 2015By targeting the HER2 protein's ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.
PET Scans Could Identify Patients With Hodgkin Lymphoma Who Don't Require Radiotherapy
May 8th 2015While some patients with Hodgkin lymphoma require radiotherapy, the risks are not necessary for a large portion of patients who can experience long-term disease-free survival with chemotherapy alone, says John Radford, MD.
Perou Discusses Genomic Characterization in Breast Cancer and Understanding Basal-Like Disease
May 8th 2015In an interview with OncLive, Charles M. Perou, MD, explains the importance of understanding and treating each subtype differently and why oncologists should be aware of the similarities between basal-like breast cancer and other non-breast cancer tumor types.
Cancer Drug Spending Hits $100 Billion
May 6th 2015Earlier diagnosis, longer treatment durations, and increased effectiveness of treatments helped to boost spending on cancer medicines to the $100 billion threshold in 2014, a rise of 10.3% for the year, and up markedly from $75 billion five years earlier.
FDA Panels Support Approval of T-VEC in Melanoma
April 29th 2015In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with advanced melanoma.
Hodi Speaks to Significance of Phase II Data on Ipilimumab Plus Nivolumab in Melanoma
April 25th 2015OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.
Inotuzumab Ozogamicin Improves Response Rates Versus Chemotherapy in Phase III ALL Study
April 23rd 2015Treatment with the antibody-drug conjugate inotuzumab ozogamicin significantly extended complete hematologic remission rates compared with chemotherapy for adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia,